Keytruda vs Verzenio
A side-by-side look at two oncology medications advertised on TV. Informational only — not medical advice.
| US Keytruda | US Verzenio | |
|---|---|---|
| Generic name | pembrolizumab | abemaciclib |
| Drug class | PD-1 Inhibitor (Immunotherapy) | CDK4/6 Inhibitor |
| Treats | Multiple cancers | HR+/HER2- breast cancer |
| Category | Oncology | Oncology |
| Manufacturer | Merck | Eli Lilly |
| Year approved | 2014 | 2017 |
| FDA warning | Moderate warnings | Moderate warnings |
| Est. TV ad spend | $260M | $85M |
| Common side effects | Immune-related side effects, Fatigue, Rash, Diarrhea | Diarrhea, Low blood counts, Fatigue, Blood clots |
Frequently asked questions
Is Keytruda or Verzenio better?
Neither is universally "better." Keytruda (pembrolizumab) and Verzenio (abemaciclib) are both used for oncology, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Keytruda and Verzenio?
Keytruda is a PD-1 Inhibitor (Immunotherapy) made by Merck, while Verzenio is a CDK4/6 Inhibitor made by Eli Lilly. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Keytruda has the larger estimated TV advertising budget of the two.